Ads
related to: pulmonary hypertension med list of drugsgoodrx.com has been visited by 100K+ users in the past month
"This free app will find the best local deals." - AOL.com
discoverpanel.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Ambrisentan is a drug that blocks endothelin, an endogenous hormone found in higher quantities in patients with pulmonary arterial hypertension. Endothelin binds to two receptors, ET A and ET B . ET A is responsible for cell growth in the vessels as well as vasoconstriction , while ET B plays a role in vasodilation , endothelin 1 clearance, and ...
Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure in the arteries of the lungs. [7] Symptoms include shortness of breath, fainting, tiredness, chest pain, swelling of the legs, and a fast heartbeat. [7] [1] The condition may make it difficult to exercise. [7] Onset is typically gradual. [8]
An endothelin receptor antagonist (ERA) is a drug that blocks endothelin receptors. Three main kinds of ERAs exist: Dual ET Receptor Antagonists, which affect both endothelin A (ET A) and B receptors (ET B) [1] aprocitentan, bosentan, macitentan, tezosentan; Selective ET A Receptor Antagonists, which affect endothelin A receptors
Merck said its drug met the main goal of significantly reducing the time to disease worsening, lung transplantation or death in a late-stage study of 172 patients with advanced stages of the ...
Bosentan, sold under the brand name Tracleer among others, is a dual endothelin receptor antagonist medication used in the treatment of pulmonary artery hypertension (PAH). [4] [5] Bosentan is available as film-coated tablets (62.5 mg or 125 mg) or as dispersable tablets for oral suspension (32 mg). [4]
Myelosuppression, pulmonary fibrosis, pulmonary infiltrates, seizure, brain oedema, cerebrospinal leaks, subdural fluid collection, intracranial infection, hypotension (uncommon), tachycardia (uncommon), decrease in kidney size (reversible), uraemia (uncommon), kidney failure (uncommon), severe hepatic toxicity (rare), thrombosis (rare) and ...